Bexorg Receives Michael J. Fox Foundation Grant to Develop TRPML1 Biomarkers for Parkinson's Disease
核心洞察
Bexorg (搜索) has been awarded a research grant from The Michael J. Fox Foundation (搜索) to identify translational biomarkers for TRPML1 (搜索)-targeted Parkinson's disease (搜索) therapies using its postmortem whole-human brain platform.
TRPML1 (搜索) has emerged as a compelling therapeutic target for Parkinson's disease (搜索), but the lack of translational biomarkers to confirm target engagement in clinical trials has been a significant obstacle.
The company will leverage its proprietary BrainEx platform to identify biomarkers in brains donated by people who lived with Parkinson's disease (搜索), potentially accelerating multiple TRPML1 (搜索)-targeted therapeutic programs.
Bexorg (搜索), Inc. has secured a research grant from The Michael J. Fox Foundation (搜索) for Parkinson's Research (MJFF) through the Targets to Therapies Initiative to identify translational biomarkers for TRPML1 (搜索)-targeted therapies. The award addresses a critical gap in Parkinson's disease (搜索) drug development, where the absence of reliable biomarkers has hindered the advancement of promising therapeutic targets.
TRPML1 Emerges as Priority Target
MJFF has convened leading experts to prioritize promising therapeutic targets for Parkinson's disease (搜索), with TRPML1 (搜索) emerging as a compelling target for drug candidates. However, the lack of translational biomarkers to confirm target engagement in clinical trials poses a significant obstacle to the advancement of TRPML1-targeted therapies.
"Through this grant, MJFF is supporting Bexorg (搜索) to leverage its postmortem whole-human brain platform in advancing TRPML1 (搜索) research to bridge the translational gap between preclinical drug discovery and advancement of therapies in clinical trials," said Paul Wes, Ph.D., Vice President of Drug Discovery at Bexorg. "With multiple biotechnology and pharmaceutical companies pursuing TRPML1-targeted programs, our collaboration with MJFF aims to accelerate the entire field toward developing disease-modifying therapies for people living with Parkinson's disease (搜索)."
Unique Platform Addresses CNS Development Challenges
Bexorg (搜索) will apply its proprietary BrainEx platform, described as the world's first postmortem whole-human brain platform, to identify biomarkers in brains donated by people who lived with Parkinson's disease (搜索). The postmortem whole brains will be sourced from LifeNet Health, an organ procurement organization that provides high-quality, ethically sourced human biological materials for research.
The approach directly addresses a fundamental challenge in CNS drug development. Industry reports have found that the clinical trial failure rate in CNS drug development exceeds 95%, largely because cellular and preclinical models used in drug discovery fail to accurately represent the complexity and biology of the human brain.
Bexorg (搜索)'s platform is built entirely on human-derived data generated from wet-lab experimentation in physiologically maintained postmortem whole human brains from people who suffered from neurological disorders or passed away from unrelated causes. This unique data set directly powers AI models that deliver high-fidelity target identification, novel biomarker discovery, and go/no-go decisions with unprecedented accuracy and reliability.
Expanding Data Repository and AI Capabilities
Since its founding in 2021, Bexorg (搜索) has rapidly advanced its drug discovery platform. Over the last 18 months, the company has expanded its proprietary data set to include hundreds of whole-brain experiments spanning Alzheimer's disease (搜索), Parkinson's disease (搜索), and other neurodegenerative conditions, creating one of the world's largest repositories of human CNS data.
Building on continuous growth of its data set, Bexorg (搜索) is now training foundation models on petabyte-scale human brain molecular data, with the goal to establish the first AI system grounded in experimentally measured human neurobiology, and redefining how CNS therapies are discovered, validated, and advanced to the clinic.
Foundation's Strategic Initiative
"Validating TRPML1 (搜索) will close important translational gaps and inform multiple therapeutic programs," said Shalini Padmanabhan, Ph.D., Senior Vice President of Translational Research at MJFF. "Bexorg (搜索)'s capabilities will help advance this work and may also inform future efforts to evaluate additional targets for Parkinson's therapies."
The Michael J. Fox Foundation (搜索) launched its Targets to Therapies Initiative in 2024 to expand the number of promising, druggable biological targets within the Parkinson's disease (搜索) translational pipeline. The initiative takes a fresh approach combining community-sourced target nomination with expert panel-guided prioritization and validation roadmaps to deliver targets that are ripe for Parkinson's therapeutic development.
Terms of the grant were not disclosed. The collaboration represents a strategic effort to accelerate the development of disease-modifying therapies for Parkinson's disease (搜索) by addressing fundamental challenges in target validation and biomarker development.